Non‐Apoptotic Inhibition of Colorectal Cancer Proliferation by Sclareol via Ferroptosis Involving SLC7A11/GPX4 Modulation

Fuente: Wiley Open Access
Guardado en:
Detalles Bibliográficos
Autores principales: Yu‐Xi Li, Yuan Wu, Qiong Li, Yu‐Qing Huang, Ying‐Ying Yuan, Yan‐Ni Su, Chien‐Shan Cheng, Lan Zheng
Formato: Artículo Open Access
Publicado: Wiley 2025
Materias:
Acceso en línea:
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
_version_ 1867014288035545088
author Yu‐Xi Li
Yuan Wu
Qiong Li
Yu‐Qing Huang
Ying‐Ying Yuan
Yan‐Ni Su
Chien‐Shan Cheng
Lan Zheng
author_facet Yu‐Xi Li
Yuan Wu
Qiong Li
Yu‐Qing Huang
Ying‐Ying Yuan
Yan‐Ni Su
Chien‐Shan Cheng
Lan Zheng
Yu‐Xi Li
Yuan Wu
Qiong Li
Yu‐Qing Huang
Ying‐Ying Yuan
Yan‐Ni Su
Chien‐Shan Cheng
Lan Zheng
collection Wiley Open Access
contents Non‐Apoptotic Inhibition of Colorectal Cancer Proliferation by Sclareol via Ferroptosis Involving SLC7A11/GPX4 Modulation Yu‐Xi Li Yuan Wu Qiong Li Yu‐Qing Huang Ying‐Ying Yuan Yan‐Ni Su Chien‐Shan Cheng Lan Zheng Phytotherapy Research ABSTRACTColorectal cancer (CRC) is a prevalent and lethal malignancy necessitating new treatments. Sclareol, the primary active component of Salvia sclarea L., exhibits diverse pharmacological properties, making it a promising anti‐cancer drug warranting further investigation. To evaluate Sclareol's action in CRC cell death, various methods were performed, including cell viability and colony formation assays, EdU assay, flow cytometry for cell cycle analysis and apoptosis, as well as TUNEL staining, transmission electron microscopy (TEM), reactive oxygen species (ROS) detection, and Fe2+ fluorometric assay. RNA sequencing and pathway analysis, combined with in silico molecular docking, and immunoblotting, were conducted to determine the mechanism of action of Sclareol. A CRC xenograft model in immunocompetent mice was used to evaluate Sclareol's in vivo efficacy and toxicity, with immunohistochemistry confirming its mechanism of action. Sclareol significantly suppressed CRC cell proliferation and induced cell cycle arrest in vitro without significantly inducing apoptosis. Ferroptosis as a promising mechanism of action was validated through TEM, ROS detection, and Fe2+ staining. RNA sequencing analysis revealed enrichment in metal ion‐transporter activity. Molecular docking analysis showed direct binding of Sclareol to the key ferroptosis‐related target solute carrier family 7 member 11 (SLC7A11). Additionally, Sclareol downregulated the expression of SLC7A11, nuclear factor erythroid 2‐related factor 2 (Nrf2), and glutathione peroxidase 4 (GPX4) proteins, indicating ferroptosis induction in vitro. Significant tumor growth inhibition was observed without hepatic or renal toxicities, with immunohistochemistry confirming the suppression of ferroptosis‐ and proliferation‐related markers in vivo. Sclareol inhibits CRC growth by modulating the ferroptosis pathway through the SLC7A11/GPX4 axis. Sclareol shows promise as a therapeutic agent in CRC, warranting further pre‐clinical studies to confirm its efficacy and safety. 10.1002/ptr.70010 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/ptr.70010
format Artículo Open Access
id wiley_oa_10_1002_ptr_70010
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Non‐Apoptotic Inhibition of Colorectal Cancer Proliferation by Sclareol via Ferroptosis Involving SLC7A11/GPX4 Modulation
Yu‐Xi Li
Yuan Wu
Qiong Li
Yu‐Qing Huang
Ying‐Ying Yuan
Yan‐Ni Su
Chien‐Shan Cheng
Lan Zheng
Phytotherapy Research
Non‐Apoptotic Inhibition of Colorectal Cancer Proliferation by Sclareol via Ferroptosis Involving SLC7A11/GPX4 Modulation Yu‐Xi Li Yuan Wu Qiong Li Yu‐Qing Huang Ying‐Ying Yuan Yan‐Ni Su Chien‐Shan Cheng Lan Zheng Phytotherapy Research ABSTRACTColorectal cancer (CRC) is a prevalent and lethal malignancy necessitating new treatments. Sclareol, the primary active component of Salvia sclarea L., exhibits diverse pharmacological properties, making it a promising anti‐cancer drug warranting further investigation. To evaluate Sclareol's action in CRC cell death, various methods were performed, including cell viability and colony formation assays, EdU assay, flow cytometry for cell cycle analysis and apoptosis, as well as TUNEL staining, transmission electron microscopy (TEM), reactive oxygen species (ROS) detection, and Fe2+ fluorometric assay. RNA sequencing and pathway analysis, combined with in silico molecular docking, and immunoblotting, were conducted to determine the mechanism of action of Sclareol. A CRC xenograft model in immunocompetent mice was used to evaluate Sclareol's in vivo efficacy and toxicity, with immunohistochemistry confirming its mechanism of action. Sclareol significantly suppressed CRC cell proliferation and induced cell cycle arrest in vitro without significantly inducing apoptosis. Ferroptosis as a promising mechanism of action was validated through TEM, ROS detection, and Fe2+ staining. RNA sequencing analysis revealed enrichment in metal ion‐transporter activity. Molecular docking analysis showed direct binding of Sclareol to the key ferroptosis‐related target solute carrier family 7 member 11 (SLC7A11). Additionally, Sclareol downregulated the expression of SLC7A11, nuclear factor erythroid 2‐related factor 2 (Nrf2), and glutathione peroxidase 4 (GPX4) proteins, indicating ferroptosis induction in vitro. Significant tumor growth inhibition was observed without hepatic or renal toxicities, with immunohistochemistry confirming the suppression of ferroptosis‐ and proliferation‐related markers in vivo. Sclareol inhibits CRC growth by modulating the ferroptosis pathway through the SLC7A11/GPX4 axis. Sclareol shows promise as a therapeutic agent in CRC, warranting further pre‐clinical studies to confirm its efficacy and safety. 10.1002/ptr.70010 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Non‐Apoptotic Inhibition of Colorectal Cancer Proliferation by Sclareol via Ferroptosis Involving SLC7A11/GPX4 Modulation
topic Phytotherapy Research
url https://onlinelibrary.wiley.com/doi/10.1002/ptr.70010